I 2010 varierte kursen mellom ca 35 og 53 kroner.
Justert for inflasjon er det mellom 49 og 74 kroner etter dagens kroneverdi.
SĂ„ selvom kursen er noe hĂžyere enn den var for 10-12 Ă„r siden er realverdien av en langsiktig investering lite Ă„ glede seg over.
Hvordan er det mulig og ha et unikt(?) produkt og sÄ gjÞre det sÄ elendig over sÄ mange Är?
Mange unge aksjonĂŠrer idag var ikke engang fĂždt da Photocure ble etablert i 1993.
Schneider har ikke vĂŠrt mannen Photocure trengte.
For Ä vÊre litt useriÞs sÄ ser jeg for meg at da han som usikker nyansatt CEO ble informert av interim CEO Dahl om at her i firmaet tar vi det med ro og lever godt med aksjonÊrenes grenselÞse tÄlmodighet.
2 Likes
Man mÄ jo bare bÞye seg i stÞvet for hvordan man kan bruke fravÊr av nye storkjÞpere til Ä styre kursen sÄpass greit uten at man dukker opp pÄ shortlister.
2 Likes
Akta infantil merking av innlegget ditt med 
Kommer ut nye poster pÄ 60 000 to ganger i dag.
Det gikk 50k pÄ 53 og 60k pÄ 54.
2 Likes
De 900 stk jeg hapsede pÄ 50,9 er jeg glad for.
Ser ud til det er vendt men holder lidt mere krudt tĂžrt.
1 Like
Hvor er det dere ser dette egentlig?
Nordnet har jo dagsomsetningen pÄ 2,5 mill.
DnB, DN Live, eller her
https://live.euronext.com/en/product/equities/no0010000045-xosl
Siden det ikke vises pÄ nordnet er dette sannsynligvis off-books eller internflyttinger⊠?
EDIT:
Avtalt omsetning / utenfor bĂžrs. Kan hende noen fikk dekket inn stuntet sitt billig.
Yahong Pharmaceutical was selected as the âTop 10 Exhibitors of Communication Influenceâ in the Innovation Incubation Zone of the 7th Expo
2025-01-24/Press Release
Shanghai, China, January 24 - The Report on the Communication Influence of the 7th China International Import Expo (hereinafter referred to as the Report) was officially released. The report is jointly compiled by the China International Import Expo Bureau and the Peopleâs Daily Public Opinion Data Center. Through rich and intuitive data and charts, it shows the communication influence of this Expo in an all-round, multi-dimensional and scientific way. Yahong Pharmaceutical was selected as the âTop 10 Exhibitors of Communication Influenceâ in the Innovation Incubation Zone of the 7th Expo.
This Expo will upgrade and create an innovation incubation zone, and display 360 innovative items from 34 countries and regions. A number of exhibits representing the development direction of new productivity, including Yahong Pharmaceutical, will be exhibited for the first time, providing assistance to the development of enterprises and achieve the improvement of scale and quality.
Yahong Pharmaceutical, together with many partners, jointly launched the first real-life exhibition of the innovative prevention and control system to accelerate the elimination of cervical cancer, as well as a variety of cutting-edge innovative products and technologies in the innovation incubation zone. The innovative product APL-1702, which is the âworldâs first and Chinaâs firstâ non-invasive treatment of pre-cervical cancer lesions, is expected to subvert the traditional surgical treatment pattern, accelerate the elimination of cervical cancer while protecting womenâs fertility, and helping China take the lead in achieving fertility-friendly cervical cancer prevention and control.
The Expo is an excellent window for China to insist on opening up to the outside world. In the future, Yahong will further deepen its communication influence and cooperate with colleagues from all walks of life to bring more innovative products to patients in China and even around the world.
About Yahong Pharmaceutical
Yahong Pharmaceutical (stock code: 688176. SH), founded in March 2010, is a global innovative pharmaceutical company focusing on the fields of genitourinary system tumors and other major diseases. Adhering to the corporate mission of âimproving human health and making life more dignifiedâ, Yahong Pharmaceutical is determined to become an international leading pharmaceutical enterprise integrating research and development, production and commercialization in the field of treatment, and provide the best integrated solutions for diagnosis and treatment for patients in China and around the world.
The company insists on taking innovative technology and products as the core driving force. By building its own research and development platform and core technology, it deeply explores the mechanism of drug action and efficiently screens and evaluates candidate drugs. Through a perfect internal research and development system and global drug development experience and expertise, Yahong Pharmaceutical is committed to launching the worldâs first-in-class drugs and other innovative drugs that have a huge unmet treatment needs in the field of treatment.
At the same time, through independent research and development and strategic cooperation, Yahong Pharmaceutical conducts in-depth layout of product pipelines around genitourinary diseases, pays great attention to the technological frontier and treatment development trends in this field, insights into and explores unmet clinical needs, forward-lookingly carrying out product planning and life cycle management, and creates a disease coverage. The product portfolio of advantages from diagnosis to treatment, so as to benefit more Chinese and global patients.
6 Likes
show me the approval
3 Likes
Still deg selv hva du tenker er sannsynlighet for approval etter resultater og slike tilbakemeldinger som er kommet fra Photocure sin partner.
50/50%?
Jeg har tror pÄ at det vil bli godkjent men er mer usikker pÄ nÄr, har mer tro pÄ at wolf scopet blir godkjent fÞr Cevira. Men har lite tro pÄ at Cevira blir godkjent pÄ under 12 mnd⊠men mener det ble tatt opp pÄ en q presentasjon ang. produktet om at dette. om det var en annen godkjennelse pga at dette ikke er ett legemiddel⊠husker ikke hva det var han sa ang det⊠skal se om jeg finner den q presentasjon og hÞre hva det var han sa.
Jeg sÄ nettopp en liste over de 300 mest shortede aksjene i Norden. Listen som er basert pÄ formidlede utlÄn av aksjer fra de stor depotbankene viser ingen utlÄn i PHO, hviket skulle indikere at det er under 0,6 % utlÄnt volum i aksjen.
NB Listene her kan av og til misse utlÄn som er gjort utenom vanlige kanaler, eller av andre grunner vÊre upresis da dette ikke nÞdvendigvis kvaltitetsikres pÄ samme mÄte som rapportering til off myndigheter.
Jepp, det er behagelig i Norge hvor man mÄ over en veldig hÞy andel som terskelverdig for at shortposisjonen din skal bli synlig, og det finnes inget mÄltall for totall short i en aksje som blir opgitt.
1 Like
Oslo BĂžrs - shorters paradise 
1 Like
Enig i at rapporteringen til markedet fra Finanstilsynet er mangelfull, hvorfor de ikke rapporterer summen av alle posisjoner over 0,2 % er for meg uforstÄelig.
Men sÄ lenge det er under 0,6 % short i aksjen sÄ er det nok begrenset hvor mye man kan skylde pÄ shortere i denne aksjen.
1 Like
Skal vel ikke vÊre sikker pÄ at det stemmer heller. SÄ vidt jeg husker har PHO ofte vÊrt blant de aksjene folk med NON melder om Ä fÄ «best» betalt for Ä lÄne ut passivt.